Successful treatment of heart failure with devices requires collaboration

Karl Swedberg, John Cleland, Martin R. Cowie, Markku Nieminen, Silvia G. Priori, Luigi Tavazzi, Dirk J. van Veldhuisen, Luis Alonso-Pulpon, John Camm, Kenneth Dickstein, Helmut Drexler, Gerasimos Filippatos, Cecilia Linde, José Lopez-Sendon, Massimo Santini, Faiez Zannad

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Implanted biventricular pacemakers (cardiac resynchronisation therapy, CRT) with or without implantable cardioverter defibrillators (ICD) improve survival and morbidity in some patients with chronic heart failure (CHF) who are optimally treated with pharmacologic agents according to current guidelines. Correspondingly, ICDs improve survival. However, there is only limited evidence for device treatment in certain patient subgroups, such as the impact of ICD on outcomes in patients with reduced ejection fraction in New York Heart Association (NYHA) Class I or IV heart failure. Similarly, limited evidence exists for CRT in patients with only modest QRS prolongation or only modestly reduced ejection fraction. Despite evidence for a beneficial effect of device therapy in CHF, only a minority of eligible patients are currently offered these options. Multiple reasons contribute to the underuse of these potentially life-saving therapies. A lack of adherence to guidelines by health care professionals is an important barrier. Clearly, efforts should be made to improve the standard of care and to familiarise all physicians involved in managing CHF patients with the indications and potential efficacy of these devices. Increased collaboration between structured heart failure care and pacemaker clinics as well as between electrophysiologists, heart failure clinicians, and primary care physicians is required. Such team collaborations should lead to improved care with reduced mortality and morbidity and increased cost effectiveness. Treatment strategy should be based on a structured approach tailored to local practice and national priorities.

Original languageEnglish
Pages (from-to)1229-1235
Number of pages7
JournalEuropean Journal of Heart Failure
Volume10
Issue number12
DOIs
Publication statusPublished - Dec 2008

Fingerprint

Treatment Failure
Heart Failure
Equipment and Supplies
Cardiac Resynchronization Therapy
Implantable Defibrillators
Morbidity
Guideline Adherence
Survival
Primary Care Physicians
Therapeutics
Standard of Care
Cost-Benefit Analysis
Guidelines
Delivery of Health Care
Physicians
Mortality

Keywords

  • Cardiac resynchronisation therapy
  • Chronic heart failure
  • Defibrillator
  • Device
  • Guidelines
  • Treatment

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Swedberg, K., Cleland, J., Cowie, M. R., Nieminen, M., Priori, S. G., Tavazzi, L., ... Zannad, F. (2008). Successful treatment of heart failure with devices requires collaboration. European Journal of Heart Failure, 10(12), 1229-1235. https://doi.org/10.1016/j.ejheart.2008.09.015

Successful treatment of heart failure with devices requires collaboration. / Swedberg, Karl; Cleland, John; Cowie, Martin R.; Nieminen, Markku; Priori, Silvia G.; Tavazzi, Luigi; van Veldhuisen, Dirk J.; Alonso-Pulpon, Luis; Camm, John; Dickstein, Kenneth; Drexler, Helmut; Filippatos, Gerasimos; Linde, Cecilia; Lopez-Sendon, José; Santini, Massimo; Zannad, Faiez.

In: European Journal of Heart Failure, Vol. 10, No. 12, 12.2008, p. 1229-1235.

Research output: Contribution to journalArticle

Swedberg, K, Cleland, J, Cowie, MR, Nieminen, M, Priori, SG, Tavazzi, L, van Veldhuisen, DJ, Alonso-Pulpon, L, Camm, J, Dickstein, K, Drexler, H, Filippatos, G, Linde, C, Lopez-Sendon, J, Santini, M & Zannad, F 2008, 'Successful treatment of heart failure with devices requires collaboration', European Journal of Heart Failure, vol. 10, no. 12, pp. 1229-1235. https://doi.org/10.1016/j.ejheart.2008.09.015
Swedberg, Karl ; Cleland, John ; Cowie, Martin R. ; Nieminen, Markku ; Priori, Silvia G. ; Tavazzi, Luigi ; van Veldhuisen, Dirk J. ; Alonso-Pulpon, Luis ; Camm, John ; Dickstein, Kenneth ; Drexler, Helmut ; Filippatos, Gerasimos ; Linde, Cecilia ; Lopez-Sendon, José ; Santini, Massimo ; Zannad, Faiez. / Successful treatment of heart failure with devices requires collaboration. In: European Journal of Heart Failure. 2008 ; Vol. 10, No. 12. pp. 1229-1235.
@article{9a6430bd19474f0582c34c86fca091e2,
title = "Successful treatment of heart failure with devices requires collaboration",
abstract = "Implanted biventricular pacemakers (cardiac resynchronisation therapy, CRT) with or without implantable cardioverter defibrillators (ICD) improve survival and morbidity in some patients with chronic heart failure (CHF) who are optimally treated with pharmacologic agents according to current guidelines. Correspondingly, ICDs improve survival. However, there is only limited evidence for device treatment in certain patient subgroups, such as the impact of ICD on outcomes in patients with reduced ejection fraction in New York Heart Association (NYHA) Class I or IV heart failure. Similarly, limited evidence exists for CRT in patients with only modest QRS prolongation or only modestly reduced ejection fraction. Despite evidence for a beneficial effect of device therapy in CHF, only a minority of eligible patients are currently offered these options. Multiple reasons contribute to the underuse of these potentially life-saving therapies. A lack of adherence to guidelines by health care professionals is an important barrier. Clearly, efforts should be made to improve the standard of care and to familiarise all physicians involved in managing CHF patients with the indications and potential efficacy of these devices. Increased collaboration between structured heart failure care and pacemaker clinics as well as between electrophysiologists, heart failure clinicians, and primary care physicians is required. Such team collaborations should lead to improved care with reduced mortality and morbidity and increased cost effectiveness. Treatment strategy should be based on a structured approach tailored to local practice and national priorities.",
keywords = "Cardiac resynchronisation therapy, Chronic heart failure, Defibrillator, Device, Guidelines, Treatment",
author = "Karl Swedberg and John Cleland and Cowie, {Martin R.} and Markku Nieminen and Priori, {Silvia G.} and Luigi Tavazzi and {van Veldhuisen}, {Dirk J.} and Luis Alonso-Pulpon and John Camm and Kenneth Dickstein and Helmut Drexler and Gerasimos Filippatos and Cecilia Linde and Jos{\'e} Lopez-Sendon and Massimo Santini and Faiez Zannad",
year = "2008",
month = "12",
doi = "10.1016/j.ejheart.2008.09.015",
language = "English",
volume = "10",
pages = "1229--1235",
journal = "European Journal of Heart Failure",
issn = "1388-9842",
publisher = "John Wiley & Sons, Ltd",
number = "12",

}

TY - JOUR

T1 - Successful treatment of heart failure with devices requires collaboration

AU - Swedberg, Karl

AU - Cleland, John

AU - Cowie, Martin R.

AU - Nieminen, Markku

AU - Priori, Silvia G.

AU - Tavazzi, Luigi

AU - van Veldhuisen, Dirk J.

AU - Alonso-Pulpon, Luis

AU - Camm, John

AU - Dickstein, Kenneth

AU - Drexler, Helmut

AU - Filippatos, Gerasimos

AU - Linde, Cecilia

AU - Lopez-Sendon, José

AU - Santini, Massimo

AU - Zannad, Faiez

PY - 2008/12

Y1 - 2008/12

N2 - Implanted biventricular pacemakers (cardiac resynchronisation therapy, CRT) with or without implantable cardioverter defibrillators (ICD) improve survival and morbidity in some patients with chronic heart failure (CHF) who are optimally treated with pharmacologic agents according to current guidelines. Correspondingly, ICDs improve survival. However, there is only limited evidence for device treatment in certain patient subgroups, such as the impact of ICD on outcomes in patients with reduced ejection fraction in New York Heart Association (NYHA) Class I or IV heart failure. Similarly, limited evidence exists for CRT in patients with only modest QRS prolongation or only modestly reduced ejection fraction. Despite evidence for a beneficial effect of device therapy in CHF, only a minority of eligible patients are currently offered these options. Multiple reasons contribute to the underuse of these potentially life-saving therapies. A lack of adherence to guidelines by health care professionals is an important barrier. Clearly, efforts should be made to improve the standard of care and to familiarise all physicians involved in managing CHF patients with the indications and potential efficacy of these devices. Increased collaboration between structured heart failure care and pacemaker clinics as well as between electrophysiologists, heart failure clinicians, and primary care physicians is required. Such team collaborations should lead to improved care with reduced mortality and morbidity and increased cost effectiveness. Treatment strategy should be based on a structured approach tailored to local practice and national priorities.

AB - Implanted biventricular pacemakers (cardiac resynchronisation therapy, CRT) with or without implantable cardioverter defibrillators (ICD) improve survival and morbidity in some patients with chronic heart failure (CHF) who are optimally treated with pharmacologic agents according to current guidelines. Correspondingly, ICDs improve survival. However, there is only limited evidence for device treatment in certain patient subgroups, such as the impact of ICD on outcomes in patients with reduced ejection fraction in New York Heart Association (NYHA) Class I or IV heart failure. Similarly, limited evidence exists for CRT in patients with only modest QRS prolongation or only modestly reduced ejection fraction. Despite evidence for a beneficial effect of device therapy in CHF, only a minority of eligible patients are currently offered these options. Multiple reasons contribute to the underuse of these potentially life-saving therapies. A lack of adherence to guidelines by health care professionals is an important barrier. Clearly, efforts should be made to improve the standard of care and to familiarise all physicians involved in managing CHF patients with the indications and potential efficacy of these devices. Increased collaboration between structured heart failure care and pacemaker clinics as well as between electrophysiologists, heart failure clinicians, and primary care physicians is required. Such team collaborations should lead to improved care with reduced mortality and morbidity and increased cost effectiveness. Treatment strategy should be based on a structured approach tailored to local practice and national priorities.

KW - Cardiac resynchronisation therapy

KW - Chronic heart failure

KW - Defibrillator

KW - Device

KW - Guidelines

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=56449129113&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56449129113&partnerID=8YFLogxK

U2 - 10.1016/j.ejheart.2008.09.015

DO - 10.1016/j.ejheart.2008.09.015

M3 - Article

C2 - 19004666

AN - SCOPUS:56449129113

VL - 10

SP - 1229

EP - 1235

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

SN - 1388-9842

IS - 12

ER -